Positions for Acadia Pharmaceuticals Inc (NASDAQ:ACAD)

“Big money sentiment for Acadia Pharmaceuticals Inc (NASDAQ:ACAD) in Q4 2018 increased to 1.11, according to Securities and Exchange Commission filings. So its up 0.19, from 2018Q3’s 0.92. 78 investment managers opened new and increased holdings, while 70 decreased and sold their holdings in Acadia Pharmaceuticals Inc so the sentiment is more positive. Funds own 135.83 million shares, up from 116.41 million shares in 2018Q3. Funds holding Acadia Pharmaceuticals Inc in top 10 decreased from 3 to 2 for a decrease of 1. In total 27 funds closed positions, 43 reduced and 48 increased. Also 30 funds bought new Acadia Pharmaceuticals Inc stakes.

Biggest Acadia Pharmaceuticals Inc Shareholders

Great Point Partners Llc owns 2.75 million shares in Acadia Pharmaceuticals Inc as of Q4 2018. As of Q4 2018, 39.71 million shares of Acadia Pharmaceuticals Inc are owned by Baker Bros. Advisors Lp. Emory University reported 122,615 shares. The Massachusetts-based fund Opaleye Management Inc. have invested about 1.18% of the institutional investor’s stock portfolio in Acadia Pharmaceuticals Inc. The New York-based fund Ghost Tree Capital Llc holds 125,000 shares or 0.71% of their portfolio.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The firm is worth $3.70 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis.Currently it has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

The stock decreased 3.41% or $0.91 during the last trading session, reaching $25.75.Currently ACADIA Pharmaceuticals Inc. is uptrending after 16.84% change in last March 6, 2018. ACAD has also 696,887 shares volume. ACAD outperformed by 12.47% the S&P500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s earnings report is awaited on May, 3., according to Faxor. The EPS diference is $0.10 or 22.73 % down from last years number. Previous year: $-0.44; Analysts forcast: $-0.54. 8.00 % negative EPS growth is what Wall Street’s forecasts after $-0.50 reported EPS previous quarter.

Jane Street Grp Ltd, a New York-based fund reported 87,180 shs. University Of Notre Dame Du Lac invested in 0.5% or 127,014 shs. The Connecticut-based Tudor Et Al has invested 0.02% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Creative Planning invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Pictet Asset Management holds 0.01% or 195,800 shs. Daiwa Grp Inc Inc holds 38,688 shs. Great West Life Assurance Company Can has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Envestnet Asset Mngmt accumulated 0% or 10,359 shs. Proshare Advisors Ltd Company invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Citigroup Incorporated owns 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 730,404 shs. Tocqueville Asset Management Ltd Partnership stated it has 51,868 shs. Qvt Financial L P stated it has 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). New York State Common Retirement Fund holds 0% or 99,400 shs. Captrust accumulated 0% or 350 shs. Vanguard Gp Inc invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

ACADIA Pharmaceuticals Inc. registered $222.45 million net activity with 2 insider purchases and 1 insider sale since September 20, 2018. On Wednesday, January 9 $200,041 worth of stock was sold by Brege Laura.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Total analysts of 9 have positions in ACADIA Pharmaceuticals (NASDAQ:ACAD) as follows: 6 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 67%. Since September 21, 2018 according to StockzIntelligence Inc ACADIA Pharmaceuticals has 11 analyst reports. On Wednesday, February 27 Needham maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating. Needham has “Buy” rating and $40 target. The company rating was maintained by Cowen & Co on Wednesday, February 27. On Thursday, November 1 the firm has “Overweight” rating by Cantor Fitzgerald given. On Wednesday, February 27 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, October 16 Cantor Fitzgerald maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating. Cantor Fitzgerald has “Overweight” rating and $27 target. On Friday, September 21 the stock has “Overweight” rating by PiperJaffray. In Wednesday, October 10 report Bank of America maintained it with “Buy” rating and $25 target. On Wednesday, February 27 the firm has “Buy” rating given by Cantor Fitzgerald.

For more ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news published briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Acadia Pharmaceuticals Becomes Oversold (ACAD) – Nasdaq” published on December 20, 2018, “Tilray (TLRY) to Report Q4 Earnings: What’s in the Cards? – Nasdaq” on February 08, 2019, “What’s in the Cards for Bausch Health (BHC) Q4 Earnings? – Nasdaq” with a publish date: February 15, 2019, “Acadia Healthcare Execs Remain Silent On Disappearance: Treatment Payment Questions Persist – Seeking Alpha” and the last “Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? – Nasdaq” with publication date: February 11, 2019.